Laya Ekhlaspour, Bruce Buckingham, Colleen Bauza, Mark Clements, Gregory P Forlenza, Anna Neyman, Lisa Norlander, Marcus Schamberger, Jennifer L Sherr, Ryan Bailey, Roy W Beck, Craig Kollman, Shannon Beasley, Erin Cobry, Linda A DiMeglio, Emily Paprocki, Michelle Van Name, Antoinette Moran
OBJECTIVES: To report the safety and side effects associated with taking verapamil for beta-cell preservation in children with newly-diagnosed T1D. RESEARCH DESIGN AND METHODS: Eighty-eight participants aged 8.5 to 17.9 years weighing ≥ 30 kg were randomly assigned to verapamil (N = 47) or placebo (N = 41) within 31 days of T1D diagnosis and followed for 12 months from diagnosis, main CLVer study. Drug dosing was weight-based with incremental increases to full dosage...
June 2024: Journal of Clinical & Translational Endocrinology